BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Drug Development

  Despite $9B Setback, Eli Lilly Boldly Moves on With Five New Alzheimer’s Candidates

  During a fireside chat at BIO in San Diego earlier this summer, Daniel Skovronsky confirmed Eli Lilly’s commitment to finding an effective therapy for ALZ’s disease.

  October 26, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Drug Development

  FDA Calls BioMarin’s Hemophilia A Drug a Breakthrough

  BioMarin announced that the FDA granted its valoctocogene roxaparvovec for Hemophilia A Breakthrough Therapy Designation.

  October 26, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Bio NC

  2 Biotech Stocks to Buy for the Next Generation

  Future generations might look back and wish their parents and grandparents had added these three top stocks to their portfolios today.

  October 26, 2017

   · 

  1 min read
• 

  Policy

  Teva Makes Move to Block Eli Lilly From Bringing Its Migraine Drug to the U.S.

  Teva said Lilly’s planned drug would infringe five patents that cover its own migraine drug, which it sought U.S. Food and Drug Administration approval for on Oct. 16.

  October 26, 2017

   · 

  1 min read
• 

  Business

  Gilead HCV Woes Continue and Investors are Spooked

  Gilead continues to see serious revenue declines in its hepatitis C marketshare, a space it has dominated for several years.

  October 26, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Deals

  Siemens Summons Three Banks for IPO of Healthineers Unit

  Siemens AG is looking to take its Healthineers unit public.

  October 26, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Job Trends

  Cambridge-Based Wave Life Sciences Expands Into New Facility Designed to House Up to 200 Employees

  Wave Life Sciences has officially opened a new state-of-the art manufacturing facility to support advancement of the company’s stereopure nucleic acid platform.

  October 26, 2017

   · 

  2 min read

   · 

  Alex Keown
• 

  Deals

  Pfizer’s $15B Consumer Health Biz May be on GlaxoSmithKline’s Shopping List

  Earlier this month, Pfizer’s chairman and CEO, Ian Read, said he was considering selling the company’s Consumer Healthcare business, or possibly spinning it off.

  October 26, 2017

   · 

  2 min read

   · 

  Mark Terry
• 

  Business

  BlueRock Therapeutics Sets Up HQ in Cambridge, Expands Executive Team

  BlueRock was founded in 2016 when Versant Ventures and Bayer invested $225 million in a Series A financing.

  October 26, 2017

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Glaxosmithkline to Build New Drug Testing Facility in Europe

  Drug giant calls for clarity on Brexit and a minimum two-year transition period to avoid disruption to medical supplies.

  October 26, 2017

   · 

  1 min read